Bayer AG stock (DE000BAY0017): S&P affirms BBB rating with negative outlook

S&P Global Ratings affirmed Bayer AG's 'BBB' long-term foreign currency credit rating on May 8, 2026, maintaining a negative outlook amid ongoing challenges.

S&P Global Ratings affirmed Bayer AG's 'BBB' long-term foreign currency credit rating on May 8, 2026, with a negative outlook. This decision reflects the company's efforts to manage debt from the Monsanto acquisition while navigating litigation risks and operational pressures, according to Cbonds citing S&P as of 05/08/2026. Bayer AG shares traded at 36.98 EUR on Xetra as of May 11, 2026, down from a previous close of 37.09 EUR, per Euronext live quotes as of 11/05/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bayer AG
• Sector/industry: Pharmaceuticals, Crop Science, Consumer Health
• Headquarters/country: Germany
• Core markets: Global, with strong US presence
• Key revenue drivers: Crop protection, pharmaceuticals, seeds
• Home exchange/listing venue: Xetra (BAYN.DE), OTC (BAYRY)
• Trading currency: EUR (primary), USD (ADR)

Bayer AG: core business model

Bayer AG operates as a life sciences company with three main divisions: Pharmaceuticals, Crop Science, and Consumer Health. The Pharmaceuticals segment focuses on prescription products in cardiology, oncology, and women's health. Crop Science provides seeds, crop protection, and digital farming solutions. Consumer Health offers non-prescription products like pain relief and skincare. This diversified model targets global markets, with significant exposure to the US through Bayer's ADR listing (BAYRY) on OTC markets, making it relevant for US retail investors tracking healthcare and agriculture sectors.

Main revenue and product drivers for Bayer AG

In the Pharmaceuticals division, key products include Xarelto for blood clot prevention and Kerendia for kidney disease, driving substantial revenue. Crop Science benefits from herbicides, fungicides, and genetically modified seeds, particularly in North America. For Q4 2025 (ended December 2025), Bayer CropScience reported standalone net profit up 179.82% to Rs 95.70 crore from Rs 34.20 crore year-over-year, per Tickertape citing Capital Market as of March 2026. Earlier, Q2 FY26 sales reached Rs 1,553.40 crore, up 10.6% YoY. These figures, published with their periods, highlight resilience in agribusiness amid volatile commodity prices.

Industry trends and competitive position

The global pharmaceuticals market faces patent cliffs and biosimilar competition, while Crop Science contends with regulatory scrutiny on GMOs and pesticides. Bayer AG holds a strong position with its integrated life sciences portfolio, competing against Syngenta, Corteva, and Pfizer. US investors note Bayer's exposure to American agriculture and healthcare spending, bolstered by Monsanto integration since 2018. The recent BAYRY ADR price rose 0.588% to $8.55 on July 25, 2025, reflecting short-term momentum, according to Stockinvest.us as of 07/25/2025.

Why Bayer AG matters for US investors

Bayer AG's US relevance stems from its Crop Science dominance in American farming and Pharmaceuticals sales in the world's largest drug market. The ADR (BAYRY) provides easy access for US retail investors, trading at $10.86 on May 8, 2026, up 0.0922%, per Stockinvest.us data. Ongoing Roundup litigation, primarily US-based, impacts sentiment but also underscores Bayer's scale in defending market-leading products.

Conclusion

The affirmation of Bayer AG's BBB rating by S&P on May 8, 2026, signals stable creditworthiness despite a negative outlook tied to debt and legal risks. Recent Crop Science earnings growth and steady ADR performance highlight operational strengths. US investors may monitor litigation resolutions and division spin-offs for potential impacts on valuation and strategy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.